MARKET

KRYS

KRYS

Krystal Biotech
NASDAQ
272.74
+5.10
+1.91%
After Hours: 278.19 +5.45 +2.00% 19:27 02/06 EST
OPEN
276.89
PREV CLOSE
267.64
HIGH
277.11
LOW
260.03
VOLUME
327.55K
TURNOVER
--
52 WEEK HIGH
295.98
52 WEEK LOW
122.80
MARKET CAP
7.91B
P/E (TTM)
40.93
1D
5D
1M
3M
1Y
5Y
1D
Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline
Simply Wall St · 4d ago
Krystal Biotech Price Target Raised to $327.00/Share From $206.00 by Goldman Sachs
Dow Jones · 5d ago
Krystal Biotech Is Maintained at Buy by Goldman Sachs
Dow Jones · 5d ago
Goldman Sachs Maintains Buy on Krystal Biotech, Raises Price Target to $327
Benzinga · 5d ago
Weekly Report: what happened at KRYS last week (0126-0130)?
Weekly Report · 5d ago
Krystal Biotech price target raised to $327 from $206 at Goldman Sachs
TipRanks · 01/30 12:37
Krystal Biotech (KRYS) Gets a Buy from H.C. Wainwright
TipRanks · 01/27 18:15
LABD: ETF To Benefit From Downturns In The Biotech Industry
Seeking Alpha · 01/26 14:19
More
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

Webull offers Krystal Biotech Inc stock information, including NASDAQ: KRYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KRYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KRYS stock methods without spending real money on the virtual paper trading platform.